LFM

LifeMD

Azione

Azione

Ticker: LFMD

LFMD

Price

Discussione su LFMD

Messaggi

8

1Mes·

LifeMD Q2 Earnings

❌ Earnings Miss

Adj. EPS: $(0.06) (vs. $(0.01) est)

YoY: ↓ 200.0% (from $0.06)

❌ Revenue Miss

Sales: $62.20M (vs. $66.34M est)

YoY: ↑ 22.8% (from $50.66M)

1

2 Commenti

immagine del profilo

1Mes

Not only hims has seasonal weakness ...

•

1

•

Mostra la risposta

2Mes·

Health sector - What do you think?

$XDWH (+0,54%)
$IUHC (+0,55%)
$WHEA (+0,2%)
$WHCS (+0,38%)
$WELS (+0,67%)
$LLY (+0,45%)
$NOVO B (+0,14%)
$RNN519 (+0,56%)

I would be interested in your opinion on the healthcare sector ? I am currently toying with the idea of parking my cash in the $XDWH (+0,54%) in the health care sector. I believe that the healthcare sector has some catching up to do and if the stock market becomes more volatile, I think the healthcare sector will benefit. Even if it is perhaps only a short-term position, I expect a higher return here than on the call money account. I like the idea, especially as the market for slimming products should continue to grow strongly and $LLY (+0,45%) ubd $NOVO B (+0,14%) will benefit from this as a dominant player.

$HIMS (-0,4%)
$LFMD

attachment

attachment

attachment

attachment

6

18 Commenti

immagine del profilo

Tenbagger2024@Tenbagger2024

2Mes

I agree with Kennedy and a few negative news items have hurt the sector.
I also see a need to catch up here.
There are some pearls in the sector in particular that can benefit enormously from AI research.
If you don't want to go pearl hunting, an ETF is of course an alternative.

•

2

•

Visualizza tutti 7 ulteriori risposte

@ApezuColabooster

4Mes·

High expectations

Added another 300 stock (for a total of 800) of $LFMD with high hopes and expectations. Focus to sell is in 1-2 years, when the company is expected to turn profitable and I am assuming the valuation will jump a lot. May hold for longer, since company may have a bright future ahead of them.

2

4Mes·

LifeMD Q1 2025 - Earnings Highlights

$LFMD earnings highlights for Q1 2025:

Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70%
Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period
Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million in the year-ago period
GAAP net income of $0.6 million or $0.01 per diluted share, delivering first-ever quarter of positive GAAP EPS
Raising full-year 2025 guidance for both total revenues and adjusted EBITDA, reflecting strong year-to-date performance in telehealth

2

@ApezuColabooster

4Mes·

They say "do not time the market", but sometimes it works out beautifully.

attachment

2

4 Commenti

immagine del profilo

StonkSniffer@ApezuColabooster

4Mes

Also, please ignore the dots being in the "wrong" place. Nordea bank marks the transactions at the daily average instead of the actual transaction price.

••

4Mes·

LifeMD expands access to Wegovy ® for self-pay patients

LifeMD is expanding access to Wegovy ® for self-pay patients through its virtual care platform by integrating NovoCare ® pharmacy. Eligible patients can now receive all FDA-approved Wegovy doses for $499/month including home delivery - no insurance required.

Source: https://ir.lifemd.com/press-release-details.php?newsId=3070180

previw image

ir.lifemd.comLifeMD

3

5Mes·

LifeMD to Accept Medicare Beneficiaries for Qualifying Virtual Primary Care

LifeMD said Thursday it expanded its insurance acceptance to include Medicare beneficiaries for qualifying virtual primary care, including weight management programs.

The company said over 21 million Medicare Part B beneficiaries in 26 states now have access to virtual care services.

LifeMD said it targets to expand access to medical services to over 60 million Medicare beneficiaries across 49 states by the end of Q2.

LifeMD shares were up more than 2% in recent trading.

6Mes·

LifeMD quarterly highlights

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%

● Adjusted EBITDA increased 78% to $9.0 million

● Telehealth adjusted EBITDA increased 396% to $5.9 million

● Full-year cash flow from operations increased 99% to $17.5 million and generated positive full-year net cash flow

● Exited 2024 with over $35 million in cash

● Introduces 2025 guidance for consolidated revenue of $265 million to $275 million and consolidated adjusted EBITDA of $30 million to $32 million

LifeMD Q4 Adj EPS $(0.02) Beats $(0.05) Estimate

Sales $64.25M Beat $57.38M Estimate

LifeMD Sees Q1 Revenue $61M-$63M Vs $59.447M Est.

FY25 Revenue $265M-$275M Vs $257.23M Est

1

Titoli di tendenza

I migliori creatori della settimana

Dati finanziari di FactSet

Partecipa alla conversazione

Iscriviti Accesso